Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Migration, Crosslink

📖

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-203-advanced-e

📖 Wiki Page

therapeutic1680 wordssynced 2026-04-02

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Change in CBS/PSP</td>
</tr>
<tr>
<td class="label">H3K9ac</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">H3K27ac</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">H4K12ac</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Global DNA methylation</td>
<td>Increased</td>
</tr>
<tr>
<td class="label">SIRT1 activity</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">BET proteins</td>
<td>Increased</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Phase 2 (PSP)</td>
</tr>
<tr>
<td class="label">Vorinostat</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Panobinostat</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">HDAC6 inhibitors</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">BRD4</td>
<td>JQ1/OTX015</td>
</tr>
<tr>
<td class="label">CHD4</td>
<td>Inhibitors</td>
</tr>
<tr>
<td class="label">MBT domain proteins</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Epigenetic Agent</td>
<td>Levodopa Interaction</td>
</tr>
<tr>
<td cla

...

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Change in CBS/PSP</td>
</tr>
<tr>
<td class="label">H3K9ac</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">H3K27ac</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">H4K12ac</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Global DNA methylation</td>
<td>Increased</td>
</tr>
<tr>
<td class="label">SIRT1 activity</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">BET proteins</td>
<td>Increased</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Phase 2 (PSP)</td>
</tr>
<tr>
<td class="label">Vorinostat</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Panobinostat</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">HDAC6 inhibitors</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">BRD4</td>
<td>JQ1/OTX015</td>
</tr>
<tr>
<td class="label">CHD4</td>
<td>Inhibitors</td>
</tr>
<tr>
<td class="label">MBT domain proteins</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Epigenetic Agent</td>
<td>Levodopa Interaction</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>↑ levels (CYP inhibition), monitor</td>
</tr>
<tr>
<td class="label">Entinostat</td>
<td>Potential interaction, monitor</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Minimal interaction</td>
</tr>
<tr>
<td class="label">JQ1 (research)</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">1</td>
<td>Valproic Acid</td>
</tr>
<tr>
<td class="label">2</td>
<td>HDAC6 Inhibitors</td>
</tr>
<tr>
<td class="label">3</td>
<td>Resveratrol</td>
</tr>
<tr>
<td class="label">4</td>
<td>BET Inhibitors</td>
</tr>
</table>

Epigenetic dysregulation is a hallmark of tauopathies including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Pathological tau accumulation is associated with widespread changes in the epigenetic landscape, including histone hypoacetylation, DNA hypermethylation, and altered chromatin accessibility. These changes contribute to transcriptional dysregulation of genes involved in neuronal survival, synaptic function, and proteostasis[@grayson2020].

This section covers pharmacological approaches to modulate the epigenetic machinery in CBS/PSP:

Histone deacetylase (HDAC) inhibitors: Restore histone acetylation balance
DNA methyltransferase (DNMT) inhibitors: Reverse abnormal DNA methylation patterns
Chromatin remodeling: BET inhibitors and chromatin reader modulators
Sirtuin modulators: Target Class III HDACs (SIRT1, SIRT2)
Drug interactions: Manage combination with levodopa and rasagiline

1. Epigenetic Dysregulation in CBS/PSP

1.1 Pathological Epigenome Changes

Mermaid diagram (expand to render)

1.2 Key Epigenetic Targets

2. Histone Deacetylase (HDAC) Inhibitors

2.1 Mechanism of Action

HDACs remove acetyl groups from histone lysine residues, leading to chromatin condensation and transcriptional repression. In CBS/PSP, HDAC activity is elevated, contributing to suppressed expression of neuroprotective genes. HDAC inhibitors restore acetyltransferase balance, reopening chromatin for transcription of survival genes[@rouaux2017].

Mermaid diagram (expand to render)

2.2 HDAC Inhibitor Classes

Class I HDAC Inhibitors (HDAC1, 2, 3, 8)

Valproic Acid (VPA)

Mechanism: Pan-class I HDAC inhibitor
Evidence: Reduces tau phosphorylation in vivo via GSK-3β inhibition[@min2019]
Dosing: 500-1000 mg/day (mood stabilizer dose)
CBS/PSP relevance: VPA shows promise but mixed results in clinical studies
Drug interactions: May affect levodopa metabolism via CYP enzyme inhibition; monitor for increased sedation when combined with rasagiline

Entinostat (MS-275)

Mechanism: Class I-selective HDAC inhibitor
Evidence: Shows neuroprotection in tauopathy models
Status: Preclinical/Phase 1

Class II HDAC Inhibitors (HDAC4, 5, 6, 9, 10)

HDAC6-Selective Inhibitors

Target: HDAC6 (cytoplasmic, deacetylates tubulin)
Examples: Tubastatin A, ACY-1215 (ricolinostat)
Mechanism: Increase tubulin acetylation, improve axonal transport
Advantage: Lower toxicity than pan-HDAC inhibitors
CBS/PSP relevance: Particularly relevant for axonal transport deficits

Class III HDAC (Sirtuin) Modulators

SIRT1 Activators

Resveratrol: 250-500 mg/day, shows cognitive benefit in some trials
SRT2104: More potent SIRT1 activator, in development
Mechanism: Deacetylates PGC-1α, FOXO, p53 — promotes mitochondrial biogenesis and stress resistance[@settel2023]

SIRT2 Inhibitors

AGK2: SIRT2-selective inhibitor
Mechanism: SIRT2 inhibition reduces tau acetylation and aggregation
Evidence: Neuroprotective in PSP models

2.3 Clinical Evidence

3. DNA Methyltransferase (DNMT) Inhibitors

3.1 DNA Methylation Abnormalities in CBS/PSP

DNA methylation patterns are altered in tauopathies, with global hypermethylation observed in brain tissue. This leads to silencing of genes involved in neuronal function, synaptic plasticity, and stress response. DNMT inhibitors can reverse these patterns[@chen2019].

Mermaid diagram (expand to render)

3.2 DNMT Inhibitor Approaches

5-Azacytidine (Vidaza)

Mechanism: Nucleoside analog incorporation into DNA → irreversible DNMT binding
Evidence: Reverses methylation in Alzheimer's models, promotes neuronal differentiation
Challenges: Hematological toxicity, limited CNS penetration
CBS/PSP relevance: Being explored for neurodegenerative applications

RG108

Mechanism: Non-nucleoside DNMT inhibitor
Advantage: Lower toxicity than nucleoside analogs
Status: Preclinical

Procaine

Mechanism: Local anesthetic with DNMT inhibitory properties
Evidence: Shows memory enhancement in AD models
Dosing: 100-200 mg/day (off-label)
Drug interactions: May interact with levodopa via shared transporters

3.3 Clinical Considerations

DNMT inhibitor therapy for neurodegenerative disease remains largely preclinical. Key challenges include:

Blood-brain barrier penetration
Off-target effects from global demethylation
Optimal dosing for CNS applications
Combination with existing therapies

4. Chromatin Remodeling Approaches

4.1 BET Bromodomain Inhibitors

BET proteins (BRD2, BRD3, BRD4, BRDT) are chromatin "readers" that bind acetylated histones and regulate transcription. In tauopathies, BET activity is elevated, driving expression of inflammatory genes and contributing to pathology. BET inhibitors block this interaction, reducing harmful transcription[@kelley2019].

JQ1

Mechanism: First-generation BET inhibitor
Evidence: Reduces tau toxicity in models, decreases neuroinflammation
Challenge: Short half-life, limited BBB penetration

OTX015 (Birabresib)

Mechanism: BET inhibitor with improved pharmacokinetics
Status: Phase 1 in oncology, being adapted for neurodegeneration
CNS penetration: Being optimized for brain delivery

IBET151

Mechanism: Second-generation BET inhibitor
Evidence: Shows efficacy in PSP models
Advantage: Better tolerability than JQ1

4.2 Chromatin Reader Modulators

4.3 Combination Approaches

Epigenetic therapies may be combined for synergistic effect:

HDAC + DNMT inhibitors: Sequential treatment to fully reset epigenetic landscape
HDAC + BET inhibitors: Target multiple levels of transcriptional dysregulation
SIRT1 activator + HDAC inhibitor: Complementary mechanisms (Class III + Class I/II)

5. Clinical Implementation

5.1 Patient Selection

Ideal candidates for epigenetic therapy:

Early-stage CBS/PSP (preserved neuronal function)
Confirmed tauopathy (tau PET positive)
Intact blood-brain barrier
No significant comorbidities

Considerations:

Genetic testing for epigenetic enzyme variants may inform response
Biomarker monitoring (neurofilament light chain) to track progression

5.2 Drug Interactions with Current Medications

Levodopa interactions:

HDAC inhibitors may affect levodopa metabolism through CYP enzyme modulation
Monitor for increased dyskinesias or reduced efficacy
Timing: Separate dosing by 2+ hours

Rasagiline interactions:

MAO-B inhibitors may have synergistic neuroprotective effects with HDAC inhibitors
Generally compatible, monitor for serotonin syndrome if adding serotonergic agents
Additive effects on mitochondrial function

5.3 NET Assessment Considerations

Norepinephrine transporter (NET) imaging can help evaluate:

Autonomic dysfunction extent
Noradrenergic pathway integrity
Potential for noradrenergic-based therapies

Combining NET assessment with epigenetic therapy monitoring may help predict response.

6. Therapeutic Recommendations

6.1 Priority Approaches

6.2 Monitoring Parameters

Biomarkers: NfL, p-tau181, GFAP every 3-6 months
Clinical: Motor Unified Parkinson's Disease Rating Scale (MDS-UPDRS), PSP Rating Scale
Imaging: MRI volumetrics, FDG-PET for metabolic response
Epigenetic markers: Where available, chromatin accessibility assays

7. Future Directions

Epigenetic editing: CRISPR-dCas9-based approaches for precise epigenetic modification (see [Epigenetic Editing and CRISPR Approaches](/therapeutics/epigenetic-editing-crispr-cbs-psp))
Combination trials: HDAC inhibitors + anti-tau antibodies
Personalized epigenomics: Patient-specific epigenetic profiling to guide therapy selection
Novel delivery: Nanoparticle-based CNS-targeted delivery of epigenetic agents

8. Key References

[Grayson et al., Epigenetic alterations in tauopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32857234/)

[Rouaux & Arendt, Class I HDAC manipulation for neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/29237839/)

[Bardai et al., HDAC dysfunction in tauopathies (2018)](https://pubmed.ncbi.nlm.nih.gov/30104761/)

[Chen et al., DNA hypomethylation in AD and tauopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/30860299/)

[Kelley et al., BET inhibition for tauopathies (2019)](https://doi.org/10.1126/scitranslmed.aau6540)

[Min et al., HDAC inhibitor valproic acid reduces tau phosphorylation (2019)](https://pubmed.ncbi.nlm.nih.gov/31145075/)

[Settel et al., Sirtuin 1 activation in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/37182145/)

[Park et al., Pan-HDAC inhibitor vorinostat in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35247632/)

[Epigenetic Editing and CRISPR Approaches in CBS/PSP](/therapeutics/epigenetic-editing-crispr-cbs-psp)
[Epigenetic Therapies for Neurodegeneration](/therapeutics/epigenetic-therapies-neurodegeneration)
[Epigenetic Reprogramming](/therapeutics/epigenetic-reprogramming)
[Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
[Molecular Chaperones](/mechanisms/molecular-chaperones)

References

[Grayson DR, et al., Epigenetic alterations in the brains of patients with tauopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32857234/)

[Rouaux C, et al., Class I HDAC manipulation for treatment of neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/29237839/)

[Bardai FH, et al., Histone deacetylase dysfunction in tauopathies (2018)](https://pubmed.ncbi.nlm.nih.gov/30104761/)

[Chen X, et al., DNA hypomethylation in Alzheimer's disease and tauopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/30860299/)

[Fischer A, et al., HDAC inhibitor therapy for cognitive enhancement (2010)](https://pubmed.ncbi.nlm.nih.gov/21045798/)

[Kelley MW, et al., BET bromodomain inhibition as a therapeutic strategy for tauopathies (2019)](https://doi.org/10.1126/scitranslmed.aau6540)

[Min SW, et al., HDAC inhibitor valproic acid reduces tau phosphorylation in vivo (2019)](https://pubmed.ncbi.nlm.nih.gov/31145075/)

[Ricotta R, et al., Epigenetic therapy for neurodegenerative disease: clinical landscape (2020)](https://pubmed.ncbi.nlm.nih.gov/32949568/)

[Settel N, et al., Sirtuin 1 activation in tauopathy models: neuroprotection mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/37182145/)

[Park J, et al., Pan-HDAC inhibitor vorinostat in PSP: mechanism and rationale (2022)](https://pubmed.ncbi.nlm.nih.gov/35247632/)

📖 View canonical wiki page →

Related Entities

therapeutics-section-203-advanced-epigenetic-chromatin-therapy-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-203-advanced-epigenetic-chromatin-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e4ce7675d841
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-203-advanced-epigenetic-chromatin-therapy-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

359

Outgoing

404

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

1. Epigenetic Dysregulation in CBS/PSP

1.1 Pathological Epigenome Changes

1.2 Key Epigenetic Targets

2. Histone Deacetylase (HDAC) Inhibitors

2.1 Mechanism of Action

2.2 HDAC Inhibitor Classes

Class I HDAC Inhibitors (HDAC1, 2, 3, 8)

Class II HDAC Inhibitors (HDAC4, 5, 6, 9, 10)

Class III HDAC (Sirtuin) Modulators

2.3 Clinical Evidence

3. DNA Methyltransferase (DNMT) Inhibitors

3.1 DNA Methylation Abnormalities in CBS/PSP

3.2 DNMT Inhibitor Approaches

3.3 Clinical Considerations

4. Chromatin Remodeling Approaches

4.1 BET Bromodomain Inhibitors

4.2 Chromatin Reader Modulators

4.3 Combination Approaches

5. Clinical Implementation

5.1 Patient Selection

5.2 Drug Interactions with Current Medications

5.3 NET Assessment Considerations

6. Therapeutic Recommendations

6.1 Priority Approaches

6.2 Monitoring Parameters

7. Future Directions

8. Key References

References

💬 Discussion

📗 Cite This Artifact

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

1. Epigenetic Dysregulation in CBS/PSP

1.1 Pathological Epigenome Changes

1.2 Key Epigenetic Targets

2. Histone Deacetylase (HDAC) Inhibitors

2.1 Mechanism of Action

2.2 HDAC Inhibitor Classes

Class I HDAC Inhibitors (HDAC1, 2, 3, 8)

Class II HDAC Inhibitors (HDAC4, 5, 6, 9, 10)

Class III HDAC (Sirtuin) Modulators

2.3 Clinical Evidence

3. DNA Methyltransferase (DNMT) Inhibitors

3.1 DNA Methylation Abnormalities in CBS/PSP

3.2 DNMT Inhibitor Approaches

3.3 Clinical Considerations

4. Chromatin Remodeling Approaches

4.1 BET Bromodomain Inhibitors

4.2 Chromatin Reader Modulators

4.3 Combination Approaches

5. Clinical Implementation

5.1 Patient Selection

5.2 Drug Interactions with Current Medications

5.3 NET Assessment Considerations

6. Therapeutic Recommendations

6.1 Priority Approaches

6.2 Monitoring Parameters

7. Future Directions

8. Key References

Related Pages

References

💬 Discussion